Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF)

T. Sakakibara, T. Fukuhara, K. Usui, M. Miki, M. Ebina, T. Nukiwa (Sendai, Japan)

Source: Annual Congress 2002 - Fungal and nocardial infections, and infections in the immunocompromised and elderly
Session: Fungal and nocardial infections, and infections in the immunocompromised and elderly
Session type: Thematic Poster Session
Number: 2190
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Sakakibara, T. Fukuhara, K. Usui, M. Miki, M. Ebina, T. Nukiwa (Sendai, Japan). Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2002; 20: Suppl. 38, 2190

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Respiratory infections in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009

Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 246s
Year: 2007

Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012


Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016


Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016

Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016


Negative outcome of prednisone in possible idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016

Diagnosis and therapy of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) in Germany
Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Year: 2018

Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR)
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020

Interstitial lung diseases in childhood
Source: ISSN=1025-448x, ISBN=1-904097-22-7, page=213
Year: 2002

Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017

RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia
Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Year: 2017




Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


Pulmonary tuberculosis (TB) as a complication of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009


Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006


Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016


LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014


LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015

Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions
Year: 2010